Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)

NCT07552077 is registered in ClinicalTrials.gov with Palvella Therapeutics, Inc. as lead sponsor.

NCT NCT07552077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Lead sponsor
Palvella Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2026
Completion date
September 30, 2027
Enrollment
15 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

angiokeratomas